Advanced search×

Overview of anti-angiogenic agents in development for ovarian cancer

Robert A Burger

Gynecol Oncol 121(1):9 (2011) PMID 21215996

Objective: To review the rationale for targeting the vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) pathways for anti-angiogenic therapy in patients with ovarian cancer and to summarize the currently available data with agents that block these pathways. Methods: Relevant papers and studies were identified by searches conducted on Medline using the terms angiogenesis, ovarian cancer, VEGF, PDGF, FGF, receptor, kinase, and inhibitor alone or in combination as well as by searches by drug name and by review of abstracts presented at recent oncology meetings. Results: The VEGF pathway is considered to be the key driver of angiogenesis, but the PDGF and FGF pathways also play important roles and may contribute to resistance to VEGF-specific blockade. Each pathway may also promote tumorigenesis; tumor cell overexpression of these growth factors and their receptors have been detected in ovarian tumor specimens, suggesting that autocrine loops may lead to tumor growth and progression. Selective inhibitors of the VEGF pathway (e.g., bevacizumab and VEGF Trap) as well as VEGF/PDGF pathway inhibitors (e.g., sorafenib and sunitinib) and VEGF/PDGF/FGF pathway inhibitors (e.g., cediranib, pazopanib, and BIBF 1120) have shown single-agent activity in women with ovarian cancer in phase II trials. Response rates of up to 21% have been reported with several agents in patients with recurrent ovarian cancer. Phase III trials with many anti-angiogenic agents in the treatment of ovarian cancer are currently ongoing. Conclusions: Anti-angiogenic agents may provide an improvement in the treatment of patients with recurrent ovarian cancer and may be useful when incorporated into first-line platinum/taxane therapy. It remains to be determined whether multitargeted agents will offer greater clinical benefit than specific VEGF pathway inhibitors.

Copyright © 2011 Elsevier Ltd. All rights reserved.

DOI: 10.1016/j.ygyno.2010.11.035
Version: za2963e q8zae q8zb8 q8zc5 q8zd0 q8ze3 q8zf3 q8zg9

Similar articles you may find interesting…

  1. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
    Frank F Hilberg, Gerald J GJ Roth, ... Wolfgang J WJ Rettig

    Cancer Res 68(12):4774-82 (2008) PMID 18559524

    Inhibition of tumor angiogenesis through blockade of the vascular endothelial growth factor (VEGF) signaling pathway is a novel treatment modality in oncology. Preclinical findings suggest that long-term clinical outcomes may improve with blockade of additional proangiogenic receptor tyrosine kinase...
  2. ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma.
    Martha M Nowosielski, Wolfgang W Recheis, ... Markus M Hutterer

    Audio, Transactions of the IRE Professio... 53(4):291-302 (2011) PMID 21125399 PMCID PMC3063200

    At 8-12 weeks follow-up, seven (50%) patients showed a partial response, three (21.4%) patients were stable, and four (28.6%) patients progressed according to RANO criteria. hT2-ADC histograms demonstrated statistically significant changes in skewness in relation to PFS at 6 months. Patients with...
    View PDF
  3. Clonal analysis reveals a common progenitor for endothelial, myeloid, and lymphoid precursors in umbilical cord blood.
    Aline Lisie AL Ramos, Radbod R Darabi, ... Rita C R RC Perlingeiro

    Circ Res 107(12):1460-9 (2010) PMID 20947832 PMCID PMC3005822

    These findings indicate that the CD34(+)CD45(+)CD133(+)CD38(+) cell fraction contains a common progenitor for the hematopoietic and vascular lineages and may represent a valuable cell source for therapeutic applications....
    View PDF